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Summary The effects of a combination of aminoglutethimide (AG) 1,000mg daily and 4-hydroxy-
androstenedione (40HA) 500 mg i.m. weekly on peripheral aromatase activity as measured by in vivo
radioisotopic tracer methodology and serum oestrogen suppression were investigated in ten post-menopausal
women with advanced breast cancer. Patients were treated for a minimum of 4 weeks with 40HA before
addition of AG for a minimum of 6 weeks. Aromatase inhibition was found to be nearly identical in the two
treatment situations (92.5 ± 4.7% and 93.8 ± 3.8% respectively). There was no further significant suppression
of plasma oestradiol or plasma oestrone levels when AG was added to 40HA treatment (mean decrease of
7.6 ± 12.1% and 2.8 ± 12.0% respectively). In contrast, adding AG caused a further suppression of plasma
oestrone sulphate (Oe,S) compared with 40HA monotherapy (mean suppression of 35.2 ± 9.1%, P<0.025).
This effect on Oe,S may be due to an influence of AG on oestrogen metabolism.
Aromatase inhibition is an established mode of treatment for
advanced post-menopausal breast cancer. The first-generation
aromatase inhibitor, aminoglutethimide (AG), has been in
clinical use for two decades (L0nning & Kvinnsland, 1988),
and currently several new aromatase inhibitors are going
through phase I-III trials (Lipton et al., 1990; Stein et al.,
1990; Evans et al., 1992; Iveson et al., 1993).
Aromatase inhibitors act by inhibiting the peripheral con-
version of circulating androgens into oestrogens. The major
oestrogen production pathway in post-menopausal women is
aromatisation of circulating androstenedione (A) into oest-
rone (Oel), while aromatisation ofcirculating testosterone (T)
into oestradiol (Oe2) is a minor pathway (Figure 1). Direct
oestrogen secretion by the ovaries and adrenal glands does
not contribute significantly to oestrogen production, and so
far no other oestrogen production pathway has been
identified in post-menopausal women (L0nning et al., 1990).
Several aromatase inhibitors, such as aminoglutethimide,
lentaron (4-hydroxyandrostenedione, 40HA) and fadrozole
(CGS 16949A), have been found to inhibit in vivo conversion
of A into Oel by >90% as measured by tracer techniques
(Santen et al., 1978; Dowsett et al., 1985; Reed et al., 1990;
L0nning et al., 1991; Jones et al., 1992). On the other hand,
plasma and urine oestrogens have consistently been reported
to be sustained at about 30-40% of their control values in
patients on treatment with these drugs (Santen et al., 1982,
1989; Dowsett et al., 1989, 1990; Johannessen et al., 1993).
Whether this discrepancy is due to technical artefacts in the
radioimmunoassays or alternative oestrogen sources in post-
menopausal women has not been resolved.
There have been different approaches to explore this
phenomenon further. In a pilot study we investigated the
effect of adding AG 1,000 mg daily to patients receiving
treatment with 40HA given in the recommended schedule of
250 mg i.m. every 2 weeks. Combined treatment caused a
further suppression of plasma oestrogens compared with
treatment with 40HA single-drug therapy, and two of the
seven patients responded clinically (L0nning et al., 1992).
This finding confirmed that sustained plasma oestrogens
found during treatment with this 40HA drug regimen could
be further suppressed, suggesting that the residual oestrogens
may not be technical artefacts. However, there could be
several explanations for this finding, such as suboptimal dos-
ing of 40HA, enhanced aromatase inhibition caused by com-
bining two drugs with different binding sites on the enzyme
or stimulation of oestrogen metabolism by AG (L0nning et
al., 1987).
This study was designed to investigate this phenomenon
further by measuring aromatase inhibition in addition to
plasma oestrogen suppression in patients treated with 40HA
given as a 'high-dose' drug regimen compared with the same
40HA regimen with AG added in concert.
Patients and methods
Patients
Ten women with advanced metastatic breast cancer suitable
for endocrine therapy were recruited. All were post-
menopausal (eight spontaneous >2 years, one surgical
ovarian ablation 21 years previously and one chemothera-
peutic ablation with LH/FSH>40 i.u. I-1). No systemic anti-
cancer treatment had been given for a minimum of 4 weeks
prior to trial entry. The protocol was approved by the local
ethical committee and all patients gave written informed
consent after distribution of information sheets. Demo-
graphic data are given in Table I.
Protocol
Patients were treated for a minimum of 4 weeks on 40HA
and thereafter for 6 weeks on combined therapy with 40HA
and AG.
Fasting blood samples for the measurement of plasma
oestrogens (Oe2, Oel and Oe,S) were taken before treatment
and at weekly intervals during treatment after at least 2
weeks on each drug schedule to ensure that steady state was
reached. Samples were taken just prior to 40HA injections.
Serum was obtained by centrifugation and was stored at
-20°C until analysis. Six patients were investigated for in
vivo aromatisation using [6,7-3H]A/[4-'4C]Oel i.v. tracer injec-
tions followed by 4 days of urine sampling as described
elsewhere to determine aromatisation (Jacobs et al., 1991).
Measurements were made before treatment, just prior to the
change to combined therapy and after 6 weeks on combined
therapy. All samples from the same patient were analysed in
the same batch.
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Figure 1 Adrenal steroidogenesis and post-menopausal oestrogen production pathway. The points of action of40HA and AG are
indicated.
Table I Demographic data for patients taking part in this investigation
Patient Age Q/I ER Metastatic sites Previous treatment
1 61 23.5 -ve Local, nodal T, chemotherapy
2 53 24.3 UK Bone T
3 61 31.2 UK Bone T
4 63 25.4 UK Bone, nodal T
5 70 27.6 UK Local, bone T
6 60 32.0 UK Bone T
7 57 30.3 +ve Local T, CGS16949A
8 69 27.1 UK Bone, nodal T
9 44 23.1 +ve Bone, local, visceral T, chemotherapy
10 64 26.2 UK Bone, local, nodal T
T, tamoxifen; UK, unknown.
Drug schedule
Based on previous endocrine data, response rates and local
side-effects, the recommended dose of 40HA is 250 mg i.m.
every 2 weeks (Dowsett et al., 1987, 1989). Recent results
suggest that a dose of 500 mg every 2 weeks causes increased
aromatase inhibition (Jones et al., 1992). The primary aim of
this study was to assess the effects of AG in patients already
having maximal aromatase inhibition on treatment with
40HA, and therefore a drug schedule of 40HA injections
500 mg weekly (the maximum dose regimen for clinical treat-
ment) was used. AG may be used at different doses varying
from 250 mg to 1,000 mg daily (L0nning & Kvinnsland,
1988). While AG may inhibit aromatase effectively at 250 mg
daily (Dowsett et al., 1985), evidence suggests that its efficacy
as an enzyme inducer and its influence on oestrogen meta-
bolism is dose dependent, with a dose of 1,000 mg daily
necessary to achieve a maximal effect (L0nning et al., 1986a,b).
Thus, AG was given as a 'high-dose drug regimen' of
1,000 mg daily (plus hydrocortisone cover 20 mg mane,
10 mg nocte).
Materials and methods
Plasma oestrogens (Oe2 and Oe,) were analysed as previously
described (Dowsett et al., 1987; Trunet et al., 1992). Oestrone
sulphate was analysed after hydrolysis, ether extraction and
column chromatography. One millilitre of serum was spiked
with approximately 1,000 c.p.m. of [6,7-3H(N)]oestrone sul-
phate (recovery control), extracted with ether to remove
unconjugated oestrone and then subjected to overnight hy-
drolysis with P-glucuronidase. The ether extracts were dried
and chromatographed on Sephadex LH-20 (dichloromethane-
ethyl acetate-methanol, 95:5:1). The fractions containing oes-
trone were pooled, evaporated and reconstituted in assay
buffer. Two aliquots of 200 .tl were assayed by the same
method as for oestrone, and 3001tl was taken to calculate
recovery. This was between 45% and 67%, and the results
were corrected for loss. The sensitivity of the assay was
25 pmol 1` and intra- and inter-assay coefficients of variation
(CVs) were 8.7% and 10.7% respectively. Reagents used and
the method of urinary HPLC analysis were as described
previously (Jacobs et al., 1991).
Statistics
When more than one sample was analysed for plasma oest-
rogens the mean value was used for statistical comparison.
Parameters obtained in the three test situations were compared
using the Friedman test for multiple comparison (two-way,
non-parametric analysis of variance). If this revealed any
difference in statistical significance between values obtained,COMBINED TREATMENT WITH AG AND 40HA 1173
paired comparison was performed by the Wilcoxon matched-
pair sign-rank test using relative values (percentage of control
values). All P-values were expressed as two-tailed.
Results
Pretreatment levels of plasma Oe2, Oel and Oe1S were 31.8 pM
(21.3-47.5 pM), 64.7 pM (47.2-88.8 pM) and 492.8 pM
(241.8-1,004.3 pM) respectively (geometric mean values with
95% confidence limits for the mean). The aromatisation rate
was 1.1% (0.6-2.0%). Treatment with 40HA alone sup-
pressed plasma Oe2, Oel and Oe1S to mean values of
40.7% ± 5.7%, 37.9% ± 3.2% and 52.0 ± 8.0% of their cont-
rols respectively (Table II). Adding AG had little effect on
plasma Oe2 and plasma Oel (producing mean values ofplasma
Oe2 and plasma Oel of 34.3% ± 3.8% and 36.9% ± 4.1% of
their controls respectively), but plasma Oe1S was suppressed to
a mean value of 39.9% ± 8.4% of control. There was a
significant overall difference between the values obtained in the
three test situations (P<0.001 for each oestrogen). There were
also significant differences between each of the plasma oest-
rogen levels in the control situation compared with (i) treat-
ment with 40HA (P<0.01) and (ii) treatment with 40HA and
AG (P<0.01). When combined treatment was compared with
treatment with 40HA alone, plasma Oe1S was further supp-
ressed by 35.2% ± 9.1% (P<0.025). However, there was no
significant difference between plasma levels of Oe2 and Oe1
obtained in the two on-treatment situations (with small inc-
reases and decreases in plasma levels of Oe2 and Oe1 of
7.6% ± 12.1% and -2.8% ± 12.0%, respectively, when values
obtained on combined treatment were compared with values
obtained during treatment with 40HA single-drug treat-
ment).
Adding AG to 40HA did not enhance aromatase inhibi-
tion. Treatment with 40HA inhibited aromatisation by a
mean value of 92.5% ± 4.7%, while treatment with 40HA
and AG in concert inhibited aromatisation by 93.8% ± 3.8%
(Table III).
Discussion
Pretreatment aromatisation rates and oestrogen values were
both within previously published ranges (Dowsett et al.,
1990, 1992; L0nning et al., 1991; MacNeill et al., 1992).
Aromatase inhibition and oestrogen suppression for 40HA
500 mg per week are in the same range as previously found
for 40HA 500 mg every 2 weeks (Dowsett et al., 1987, 1989;
Jones et al., 1992).
While aromatase inhibitors have proved to be an effective
and useful treatment modality in advanced breast cancer,
several major questions related to their mechanisms of action
remain to be addressed. Firstly, there is a discrepancy
between results obtained by tracer studies revealing >90%
aromatase inhibition and the finding of plasma oestrogens
sustained at 30-40% of their control levels. Secondly, it is
not clear whether different aromatase inhibitors may have an
additive influence on the aromatase system, as suggested
from in vitro studies (Santner et al., 1983). Thirdly, the
influence of AG on oestrogen metabolism merits separate
consideration. These problems remain to be addressed
meticulously to assess the important question of a dose-
response relationship between clinical response rates and
either plasma oestrogen suppression or the percentage of
aromatase inhibition in patients receiving treatment with
aromatase inhibitors.
This investigation was designed to explore further the
influence of 40HA and AG on oestrogen disposition. In a
previous trial we showed that giving AG 1,000 mg daily to
patients being treated with 40HA further enhanced plasma
oestrogen suppression (L0nning et al., 1992). There may be
several explanations for this finding. While the dose of
40HA used in that investigation (250 mg every 2 weeks) is
the dose recommended for clinical treatment and is found to
suppress plasma oestrogens effectively (Dowsett et al., 1987,
1989), recent findings from our group suggest that higher
doses (such as 500 mg every 2 weeks) may cause a somewhat
better aromatase inhibition in vivo (Jones et al., 1992). Thus,
to address the possibility that our previous findings may have
Table II Residual oestrogen as a percentage of pretreatment values for Oel, Oe2, and Oe1S during treatment with 40HA
alone and 40HA combined with AG, and the percentage difference between the two on-treatment situations
Oe2 Oe, Oe,S
Patient 40HA +AG Difference (%) 40HA +AG Difference (%) 40HA +AG Difference (%)
1 26 46 -76 33 23 29 20 6 69
2 67 39 41 29 38 -28 68 60 12
3 39 23 42 41 25 39 70 43 38
4 52 45 13 42 47 -11 27 15 45
5 19 16 16 46 18 60 30 11 65
6 23 17 23 23 34 -45 60 47 22
7 33 44 -30 52 39 26 65 40 39
8 26 31 -18 24 35 -44 * 55 *
9 62 36 42 39 51 -31 * * *
10 61 47 23 48 59 -23 77 83 -7
Mean difference (%) (± s.e.m.) 7.6 -2.8 35.2
(± 12.1) (±12.0) (±9.1)
*No measurement.
Table III Peripheral aromatase activity (AA) and percentage inhibition before and during
treatment with 40HA alone and 40HA combined with AG
Before 40HA 40HA/AG
Patient no. AA AA Inhibition (%) AA Inhibition (%)
1 1.3 0.1 92.5 0.06 95.5
2 0.8 0.02 97.8 0.04 95.2
3 2.8 0.3 88.5 0.3 88.9
4 1.6 0.02 98.5 0.03 98.4
5 1.4 0.2 89.2 0.2 89.2
6 1.0 0.1 88.3 0.05 95.3
Mean inhibition (%) (± s.e.m.) 91.3 94.2
(± 1.9) (± 1.4)1174 F.A. MACNEILL et al.
been due to incomplete inhibition by 40HA, we selected a
'high-dose' drug schedule of 40HA 500 mg weekly for this
investigation.
The results obtained in this study add to our understand-
ing of our previous findings. In the previous investigation, we
found that AG 1,000 mg daily caused a further suppression
of plasma Oel and Oe2 by mean values of 40% and of
plasma Oe,S by a mean value of about 60% when added to a
drug schedule of 40HA 250 mg i.m. every 2 weeks (L0nning
et al., 1992). In the present investigation, we found that AG
produced no further suppression of plasma Oel and Oe2 but
a further suppression of plasma Oe,S by a mean of 32.9%
when added to 40HA given as a 'high-dose drug schedule' of
500 mg weekly. In addition, this study revealed that AG
caused no further enhancement of aromatase inhibition when
added to this 'high-dose' 40HA schedule. In our opinion, the
findings of the two studies are in accordance with each other
and may be interpreted as follows. As discussed above,
40HA given in a drug schedule of 250 mg every 2 weeks
causes incomplete aromatase inhibition compared with a
dose of 500 mg (Jones et al., 1992). This submaximal
aromatase inhibition may be further enhanced either by in-
creasing the 40HA dose or by adding another aromatase
inhibitor, such as AG. However, if 40HA is given at a dose
of 500 mg per week, adding AG may not significantly
enhance aromatase inhibition and would not be expected to
have any significant influence on plasma Oel and Oe2. In
contrast, adding AG to this high-dose 40HA regimen prob-
ably further suppresses plasma Oe1S by enhancing plasma
OejS metabolism (L0nning et al., 1987, 1989).
It is noteworthy that there was a substantial inter-
individual variation in the plasma Oe1S suppression achieved
by adding AG. At this stage we have no explanation for this
discrepancy. Clearly, this needs to be addressed in a larger
number of patients to determine if this variability is related
to other patient characteristics.
While AG did not enhance aromatase inhibition when
added to 'high-dose' 40HA treatment, this finding does not
exclude the possibility that other aromatase inhibitors may
have additive effects on the aromatase enzyme. It should be
noted that AG is a potent enzyme inducer, enhancing the
metabolism of many drugs (L0nning et al., 1984), including
anti-tumour drugs such as tamoxifen and the progestins
megestrol acetate and medroxyprogesterone acetate (Lien et
al., 1990; Lundgren et al., 1990). We did not have the
opportunity to evaluate plasma levels of 40HA in this in-
vestigation, and so we cannot exclude the possibility that AG
may enhance 40HA metabolism and reduce 40HA plasma
levels. On the other hand, it should be recalled that the dose
of 40HA used in this investigation (500mg per week) is
twice the dose previously reported to cause optimal
aromatase inhibition (Jones et al., 1992). Thus, even if a drug
interaction cannot be excluded, it is questionable whether it
would be of clinical significance with the high doses of
40HA used in this investigation.
Conclusion
In conclusion, this work suggests that AG causes enhanced
suppression of Oel and Oe2 in patients on treatment with
40HA only when the dose of 40HA is such that it achieves
submaximal aromatase inhibition. However, further suppres-
sion ofOe1S may be achieved by the specific effects ofAG on
the metabolism ofOe1S. It has been suggested that Oe1S may
be an important precursor to intracellular oestrogens (Sant-
ner et al., 1984), but the absolute contribution of this hor-
mone to intracellular oestrogen concentrations is not known.
If plasma Oe1S is a major contributor to intracellular oestro-
gens, the possibility exists that this may be a mechanism of
biological importance contributing to the anti-tumour effect
of AG. This possibility merits investigation in future
trials.
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